Lawyers and Settlements
Home Page >> Potential Lawsuit >> Allergan Accused of Keeping Generic Restasis Off the Market

Allergan Accused of Keeping Generic Restasis Off the Market

Dallas, TX: Allergan could be facing a proposed antitrust class action lawsuit based on allegations made by direct purchases of the pharmaceutical company’s Restasis, a medication for dry eyes. The plaintiffs allege that Allergan blocked low-cost generic versions from entering the market.

The allegations state that had Allergan not been engaged in actions that delayed or stopped generic versions of Restasis from reaching the marking, those generic versions would have become available as early as May 2014, which could have been purchased at a fraction of the cost of Restasis.

Instead, the lawsuit alleges, Allergan has violated the Sherman Act by using a multifaceted approach to keep generics off the market. Its actions allegedly included blocking low-cost generics for the dry-eye medication through improperly obtained patents, sham infringement suits and citizen petitions, and partnering with a Native American tribe to avoid patent challenges.

Restasis Legal Help

If you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Published on Nov-22-17


Posted by
Susan Fuentes
I used Restasis for 12 years. I developed a tumor in my back the size of a Valencia orange. It was under my bone. I had to have a major surgery In April 2011 to remove it. The tumor was tested at the cancer center and I was contacted by Allergan directly and they let me know the tumor was caused by long term use of Restatis.


Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.